529 related articles for article (PubMed ID: 30219235)
1. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
[TBL] [Abstract][Full Text] [Related]
2. Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines.
Sasaki R; Kanda T; Fujisawa M; Matsumoto N; Masuzaki R; Ogawa M; Matsuoka S; Kuroda K; Moriyama M
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397371
[TBL] [Abstract][Full Text] [Related]
3. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
7. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
8. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
9. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
[TBL] [Abstract][Full Text] [Related]
10. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
D'Alessandro R; Refolo MG; Lippolis C; Giannuzzi G; Carella N; Messa C; Cavallini A; Carr BI
BMC Cancer; 2014 May; 14():351. PubMed ID: 24885890
[TBL] [Abstract][Full Text] [Related]
14. Apatinib Inhibits the Invasion and Metastasis of Liver Cancer Cells by Downregulating MMP-Related Proteins via Regulation of the NF-
He X; Huang Z; Liu P; Li Q; Wang M; Qiu M; Xiong Z; Yang S
Biomed Res Int; 2020; 2020():3126182. PubMed ID: 32685465
[TBL] [Abstract][Full Text] [Related]
15. Novel strategies for hepatocellular carcinoma based on MMPs science.
Okazaki I; Inagaki Y
Anticancer Agents Med Chem; 2012 Sep; 12(7):753-63. PubMed ID: 22292750
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
17. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M
Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791
[TBL] [Abstract][Full Text] [Related]
18. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
Yu CC; Huang SY; Chang SF; Liao KF; Chiu SC
Molecules; 2020 May; 25(10):. PubMed ID: 32466169
[TBL] [Abstract][Full Text] [Related]
19. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J
Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
